- Home
- NXGL vs CMMB Comparison
NXGL vs CMMB Comparison
Compare NXGL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- CMMB
- Stock Information
- Founded
- NXGL 1997
- CMMB 2004
- Country
- NXGL United States
- CMMB Israel
- Employees
- NXGL N/A
- CMMB N/A
- Industry
- NXGL Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- CMMB Health Care
- Exchange
- NXGL Nasdaq
- CMMB Nasdaq
- Market Cap
- NXGL 19.7M
- CMMB 23.0M
- IPO Year
- NXGL 2021
- CMMB N/A
- Fundamental
- Price
- NXGL $2.65
- CMMB $1.21
- Analyst Decision
- NXGL
- CMMB Strong Buy
- Analyst Count
- NXGL 0
- CMMB 2
- Target Price
- NXGL N/A
- CMMB $8.50
- AVG Volume (30 Days)
- NXGL 41.5K
- CMMB 186.3K
- Earning Date
- NXGL 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- NXGL N/A
- CMMB N/A
- EPS Growth
- NXGL N/A
- CMMB N/A
- EPS
- NXGL N/A
- CMMB N/A
- Revenue
- NXGL $10,228,000.00
- CMMB N/A
- Revenue This Year
- NXGL $52.35
- CMMB N/A
- Revenue Next Year
- NXGL $42.38
- CMMB N/A
- P/E Ratio
- NXGL N/A
- CMMB N/A
- Revenue Growth
- NXGL 116.01
- CMMB N/A
- 52 Week Low
- NXGL $1.95
- CMMB $0.87
- 52 Week High
- NXGL $5.10
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- NXGL 60.17
- CMMB 37.38
- Support Level
- NXGL $2.31
- CMMB $1.17
- Resistance Level
- NXGL $2.78
- CMMB $1.22
- Average True Range (ATR)
- NXGL 0.20
- CMMB 0.06
- MACD
- NXGL 0.04
- CMMB -0.01
- Stochastic Oscillator
- NXGL 74.53
- CMMB 37.50
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.